101 related articles for article (PubMed ID: 9892848)
1. The role of N-methyl-D-aspartate receptors in the release of adrenocorticotropin by dynorphin A1-13.
Szeto HH; Soong Y; Wu D
Neuroendocrinology; 1999 Jan; 69(1):28-33. PubMed ID: 9892848
[TBL] [Abstract][Full Text] [Related]
2. Dynorphin A1-13 stimulates ovine fetal pituitary-adrenal function through a novel nonopioid mechanism.
Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
J Pharmacol Exp Ther; 1997 Jan; 280(1):416-21. PubMed ID: 8996223
[TBL] [Abstract][Full Text] [Related]
3. Site and mechanism of action of dynorphin A-(1-13) and N-methyl-D-aspartate on ACTH release in fetal sheep.
Nardo L; Soong Y; Wu D; Young IR; Walker D; Szeto HH
Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1301-7. PubMed ID: 12006360
[TBL] [Abstract][Full Text] [Related]
4. Dynorphin stimulates corticotropin release from mouse anterior pituitary AtT-20 cells through nonopioid mechanisms.
Cheng PY; Birk AV; Gershengorn MC; Szeto HH
Neuroendocrinology; 2000 Mar; 71(3):170-6. PubMed ID: 10729788
[TBL] [Abstract][Full Text] [Related]
5. Dynorphin A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism.
Tang Q; Lynch RM; Porreca F; Lai J
J Neurophysiol; 2000 May; 83(5):2610-5. PubMed ID: 10805661
[TBL] [Abstract][Full Text] [Related]
6. Differential mechanisms of ovine fetal pituitary stimulation by a selective kappa-opioid agonist and by dynorphin.
Taylor CC; WU D; Soong Y; Yee JS; Szeto HH
Neuroendocrinology; 1996 Dec; 64(6):419-24. PubMed ID: 8990074
[TBL] [Abstract][Full Text] [Related]
7. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.
Schoffelmeer AN; Hogenboom F; Mulder AH
Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509
[TBL] [Abstract][Full Text] [Related]
8. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism.
Tan-No K; Esashi A; Nakagawasai O; Niijima F; Tadano T; Sakurada C; Sakurada T; Bakalkin G; Terenius L; Kisara K
Brain Res; 2002 Oct; 952(1):7-14. PubMed ID: 12363399
[TBL] [Abstract][Full Text] [Related]
9. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
J Pharmacol Exp Ther; 1996 May; 277(2):877-84. PubMed ID: 8627570
[TBL] [Abstract][Full Text] [Related]
10. Dynorphin uses a non-opioid mechanism to potentiate N-methyl-D-aspartate currents in single rat periaqueductal gray neurons.
Lai SL; Gu Y; Huang LY
Neurosci Lett; 1998 May; 247(2-3):115-8. PubMed ID: 9655606
[TBL] [Abstract][Full Text] [Related]
11. Dynorphin and the hypothalamo-pituitary-adrenal axis during fetal development.
Szeto HH
Life Sci; 2003 Jun; 73(6):749-58. PubMed ID: 12801596
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-D-aspartate treatment increases circulating adrenocorticotropin and luteinizing hormone in the rat.
Farah JM; Rao TS; Mick SJ; Coyne KE; Iyengar S
Endocrinology; 1991 Apr; 128(4):1875-80. PubMed ID: 1848504
[TBL] [Abstract][Full Text] [Related]
13. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons.
Hauser KF; Foldes JK; Turbek CS
Exp Neurol; 1999 Dec; 160(2):361-75. PubMed ID: 10619553
[TBL] [Abstract][Full Text] [Related]
14. Acute N-methyl-D,L-aspartate administration stimulates the luteinizing hormone releasing hormone pulse generator in the ovine fetus.
Bettendorf M; de Zegher F; Albers N; Hart CS; Kaplan SL; Grumbach MM
Horm Res; 1999; 51(1):25-30. PubMed ID: 10095166
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, nonopioid metabolites.
Hauser KF; Knapp PE; Turbek CS
Exp Neurol; 2001 Mar; 168(1):78-87. PubMed ID: 11170722
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subunits to inhibition by dynorphin.
Brauneis U; Oz M; Peoples RW; Weight FF; Zhang L
J Pharmacol Exp Ther; 1996 Dec; 279(3):1063-8. PubMed ID: 8968325
[TBL] [Abstract][Full Text] [Related]
17. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors.
Laughlin TM; Vanderah TW; Lashbrook J; Nichols ML; Ossipov M; Porreca F; Wilcox GL
Pain; 1997 Aug; 72(1-2):253-60. PubMed ID: 9272810
[TBL] [Abstract][Full Text] [Related]
18. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity.
Skilling SR; Sun X; Kurtz HJ; Larson AA
Brain Res; 1992 Mar; 575(2):272-8. PubMed ID: 1349253
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) results in stressor-specific inhibition of prolactin and corticotropin release.
Zelena D; Makara GB; Jezova D
Neuroendocrinology; 1999 May; 69(5):316-23. PubMed ID: 10343172
[TBL] [Abstract][Full Text] [Related]
20. Adrenocorticotrophin and luteinizing hormone responses to N-methyl-D-aspartate during fetal development in sheep.
Brooks AN; Howe DC
J Neuroendocrinol; 1996 Apr; 8(4):315-21. PubMed ID: 8861288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
